Application of edaravone and dexborneol in patients with acute ischemic stroke
Objective To analyze the application effect of edaravone and dexborneol in patients with acute ischemic stroke(AIS).Methods 99 patients with acute ischemic stroke were divided into a study group(50 cases)and a control group(49 cases)according to a random number table method.Both groups received intravenous thrombolysis,on this basis,the control group received routine symptomatic treatment,while the study group received edaravone and dexborneol treatment on the basis of the control group.The clinical efficacy,oxidative stress index[malondialdehyde(MDA),superoxide dismutase(SOD)]and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 94.00%,which was higher than 75.51%of the control group(P＜0.05).Before treatment,there was no difference in MDA and SOD levels between the two groups(P＞0.05).After treatment,the study group had lower MDA of(4.55±0.56)μmol/L than(6.40±0.89)μmol/L in the control group,and higher SOD of(95.65±12.66)U/ml than(79.50±13.06)U/ml in the control group(P＜0.05).There was no difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Edaravone and dexborneol can effectively improve neurological function and inhibit oxidative stress in patients with acute ischemic stroke with high safety,which contains clinical application and promotion value.
Edaravone and dexborneolAcute ischemic strokeNeurological function
NETL
NSTL
万方数据
维普
